key: cord-0901555-klky357b
authors: Dias, Leonor; Soares-dos-Reis, Ricardo; Meira, João; Ferrão, Diana; Soares, Pedro Ribeirinho; Pastor, Ana; Gama, Guilherme; Fonseca, Luísa; Fagundes, Vítor; Carvalho, Marta
title: Cerebral Venous Thrombosis after BNT162b2 mRNA SARS‑CoV‑2 vaccine
date: 2021-05-25
journal: J Stroke Cerebrovasc Dis
DOI: 10.1016/j.jstrokecerebrovasdis.2021.105906
sha: fc194d073a47b45225528b3abd24fec9d69ca90e
doc_id: 901555
cord_uid: klky357b

The development of SARS-CoV-2 vaccines has raised several concerns regarding venous thromboembolism, namely cerebral venous thrombosis. Although cerebral venous thrombosis has been reported after administration of a viral vector vaccine, due to a possible auto-immune mechanism inducing thrombocytopenia, the same has not happened in mRNA vaccines. We report two cases of cerebral venous thrombosis, shortly after administration of mRNA vaccine. In both patients, there was no evidence of thrombocytopenia or antiplatelet antibodies, and alternative causes for cerebral venous thrombosis were found. As such, despite the temporal relation of both cases to vaccine administration, these types of cerebral venous thrombosis do not seem to be pathophysiological different from cerebral venous thrombosis not associated to SARSCoV-2 vaccination. Continuous pharmacovigilance is necessary to monitor possible new events and clarify this association

Leonor Dias* 1, 2 , Ricardo Soares-dos-Reis* 1 This study did not receive grant support.

contribute as a trigger for thromboembolic events. This mechanism is different from the AstraZeneca vaccine (ChAdOx1 nCoV-19, Vaxzevria  ) and Janssen vaccine (Ad26.COV2.S), which use a viral vector.

Up to 08/05, 70 cases of CVT with AstraZeneca's vaccine have been reported in EudraVigilance and 5 cases with Janssen's, most occurring in women aged under 60, up to 2 weeks post-vaccination 3, 5, 9 . These cases had thrombocytopenia and antiplatelet-PF4-antibodies, with a probable auto-immune mechanism leading to an atypical form of immune thrombocytopenia 10 . Although the exact pathophysiological mechanism for this type of thrombosis is still not clear, patients seem to benefit from immunomodulatory therapy (with intravenous immunoglobulin and high dose corticosteroids), and a proposed treatment mechanism with immunomodulation and non-heparin-anticoagulation has recently been published 11 .

However, our cases did not exhibit thrombocytopenia nor antiplatelet antibodies. There was no clinical or laboratory worsening after the start of enoxaparin. Moreover, both had good clinical outcome, with no or minor neurological deficits, and had additional CVT risk factors: combined hormonal contraception and a likely malignant renal neoplasm. Thus, despite the temporal relation with vaccination, these cases do not seem to be pathophysiologically different from regular CVT. Continuous pharmacovigilance is necessary to monitor adverse events and clarify this association.

Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence?

Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots. BMJ; 372. Epub ahead of print 2021

Vaxzevria (previously COVID-19 Vaccine AstraZeneca): link between the vaccine and the occurrence of thrombosis in combination with thrombocytopenia

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination

COVID-19 Vaccine Janssen: link between the vaccine and the occurrence of thrombosis in combination with thrombocytopenia

US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination

Safety and Efficacy of the BNT162b2 mRNA Covid-19

Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to "potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases

EudraVigilance -European database of suspected adverse drug reaction reports

AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets